We postulate that the differential therapeutic effect of ILKI in MDA‐MB‐231 and MCF‐7 3D tumoroid models with distinct stromal compositions can be explained by the interplay between stromal cell and cancer cell type [57], ECM remodeling, and ILK‐driven signaling pathways. The gene discussed is ILK; the disease is cancer.